Table 4.

Clinical response (SRI) to treatment at weeks 12 and 24: ITT target population* analysis

	Lupuzor
	Group 1 (200 μg every 4 weeks)	Group 2 (200 μg every 2 weeks)	Group 3 (placebo)
Week 12	n=42	n=48	n=44
Responders, n (%)	26 (61.9)	23 (48.0)	17 (38.6)
	p=0.016	p=0.18	–
Week 24	n=42	n=48	n=46
Responders, n (%)	29 (69.1)	30 (62.5)	26 (56.5)
	p=0.11	p=0.28	–

*Corresponds to all ITT patients having a clinical SLEDAI ≥6 at week 0.

p Values compare Lupuzor with placebo.

ITT, intention-to-treat; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SRI, SLE Responder Index.